|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0032854,
umls-concept:C0033325,
umls-concept:C0185117,
umls-concept:C0521115,
umls-concept:C0681842,
umls-concept:C0740457,
umls-concept:C1332823,
umls-concept:C1561558,
umls-concept:C1835886,
umls-concept:C2911684
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-1-4
|
|
pubmed:abstractText |
CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors and outcome according to the expressions of CXCR4 and CXCR7 in renal cell carcinoma (RCC). CXCR4 and CXCR7 expression was evaluated in 223 RCC patients through immunohistochemistry; moreover CXCR4 and CXCR7 was detected in 49 others consecutive RCC patients trough RT- PCR. CXCR4 expression was low in 42/223 RCC (18.8%), intermediate in 71/223 (31.9%) and high in 110/223 (49.3%). CXCR7 expression was low in 44/223 RCC patients (19.8%), intermediate in 65/223 (29.1%) and high in 114/223 (51.1%). High CXCR4 and high CXCR7 expression predicted shorter disease free survival. In multivariate analysis, high CXCR4 expression (p= 0.0061), high CXCR7 (p= 0.0194) expression and the concomitant high expression of CXCR4 and CXCR7 (p= 0.0235) are independent prognosis factors. Through RT-PCR, CXCR4 was overexpressed in 36/49 and CXCR7 in 33/49 samples correlating with symptoms at diagnosis and lymph nodes status. So we can hypothesize that CXCR4 and CXCR7, singularly evaluated and in combination, are valuable prognostic factors in RCC patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1873-5576
|
|
pubmed:author |
pubmed-author:CalemmaRR,
pubmed-author:CartenìGG,
pubmed-author:CastellsCC,
pubmed-author:CindoloLL,
pubmed-author:CioffiMM,
pubmed-author:ClaudioLL,
pubmed-author:ConsalesCC,
pubmed-author:CostantiniSS,
pubmed-author:D'AlterioCC,
pubmed-author:FacchiniGG,
pubmed-author:FrancoRR,
pubmed-author:LongoNN,
pubmed-author:MarrePP,
pubmed-author:OttaianoAA,
pubmed-author:PerdonàSS,
pubmed-author:PignataSS,
pubmed-author:PolimenoMM,
pubmed-author:PortellaLL,
pubmed-author:PucciLL,
pubmed-author:ScalaSS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
772-81
|
|
pubmed:meshHeading |
pubmed-meshheading:20578990-Aged,
pubmed-meshheading:20578990-Aging,
pubmed-meshheading:20578990-Carcinoma, Renal Cell,
pubmed-meshheading:20578990-Disease-Free Survival,
pubmed-meshheading:20578990-Female,
pubmed-meshheading:20578990-Humans,
pubmed-meshheading:20578990-Immunohistochemistry,
pubmed-meshheading:20578990-Kidney,
pubmed-meshheading:20578990-Kidney Neoplasms,
pubmed-meshheading:20578990-Lymphatic Metastasis,
pubmed-meshheading:20578990-Male,
pubmed-meshheading:20578990-Neoplasm Recurrence, Local,
pubmed-meshheading:20578990-Neoplasm Staging,
pubmed-meshheading:20578990-Prognosis,
pubmed-meshheading:20578990-RNA, Messenger,
pubmed-meshheading:20578990-Receptors, CXCR,
pubmed-meshheading:20578990-Receptors, CXCR4,
pubmed-meshheading:20578990-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20578990-Survival Analysis
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.
|
|
pubmed:affiliation |
Department of Oncological Immunology, National Cancer Institute, Naples, G. Pascale, Via Semmola, 80131 Naples, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
